| 摘要 |
The disclosure provides an oral pharmaceutical formulation in the form of a capsule comprising melphalan 0.3-2wt%, polyvinyl pyrrolidone or microcrystalline cellulose 50-96wt%, sodium lauryl sulfate and/or poloximer 188 0-10wt%, L-HPC, sodium croscarmellose and/or crospovidone 2-10wt%, silicone dioxide and/or talc 0-5wt%, and magnesium stearate 0-3wt%, based on the total weight of the formulation. The pharmaceutical formulation provides high stability and superior bioavailability. |
